Ticarcillin 3g / Clavulanic acid 200mg powder for solution for infusion vials
Official documents, adverse reaction reporting, and safety monitoring
Report a side effect
Submit a Yellow Card report to the MHRA
Official medicine documents
Yellow Card
Report side effects (MHRA)
Drug safety updates
MHRA alerts for Ticarcillin + Clavulanic acid
Safety monitoring data
Yellow Card reports
The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.
View Drug Analysis Profile
Browse all Drug Analysis Profiles A–Z
Browse all iDAP reports
Interactive Drug Analysis Profiles for all medicines
Report a side effect
Submit a Yellow Card report to the MHRA
Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.
EudraVigilance
The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.
Search EudraVigilance database
Browse substances A–Z in the European adverse reaction database
About EudraVigilance
Learn about EU pharmacovigilance and safety monitoring
EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.
1 branded products available
WHO defined daily dose (DDD)
15 gram
Not a recommended dose. The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. It is a statistical measure used for research and comparison purposes only.
Source: WHO Collaborating Centre for Drug Statistics Methodology, distributed via the NHS dm+d supplementary mapping files (NHSBSA). Contains public sector information licensed under the Open Government Licence v3.0.
Therapeutically similar medicines
Similarity is based on WHO Anatomical Therapeutic Chemical (ATC) classification and on a factual NHS dm+d therapeutic-grouping code prefix. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.
NHS prescribing volume and spending trends
Check stock at pharmacies and supply information
Pharmacy stock checkers
Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.
Supply & safety information
Official UK regulator monitoring and safety alerts
Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. Shortage and safety information sourced from MHRA drug safety updates (gov.uk, Crown Copyright under OGL v3.0).
Codes for healthcare professionals and prescribing systems
These codes are used by healthcare IT systems and prescribers to identify this medicine.
NHS UK identifiers
Browse tools
SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. ATC codes from the WHO Collaborating Centre for Drug Statistics Methodology (whocc.no).
Active and completed clinical studies from ClinicalTrials.gov
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.
Academic studies and reviews for this medicine's active substance
Showing the 50 most relevant studies.
Reviews & meta-analyses: 2 · Randomised trials: 3 · Trials: 1 · 1978–2026
Showing the 50 most relevant studies, sorted by most relevant.
Sameni F, Dadashi A, Hajikhani B, et al.
2025
BackgroundInfections caused by Stenotrophomonas maltophilia (S. maltophilia) are particularly difficult to treat because of their intrinsic resistance to multiple antibiotics.ObjectiveThe main aim of this systematic review was to evaluate the prevalence of infections caused by this bacterium across different provinces of Iran. Additionally, the study assessed the resistance rates of commonly prescribed antibiotics to address existing gaps in therapeutic knowledge.MethodsA systematic literature review was conducted to identify relevant original research articles published in English between 2000 and 2024, using Google Scholar, Medline (via PubMed), Embase, and Web of Science. Following screening, all studies reporting antibiotic resistance in clinical isolates of S. maltophilia from Iran were included and analyzed.ResultsA total of 1415 clinical isolates were collected from 16 regions across Iran. Most isolates showed high susceptibility to ticarcillin/clavulanic acid and minocycline (98.5 % and 98.2 %, respectively). Among the genes associated with biofilm formation and antibiotic resistance, sul1 and spgM were the most prevalent (12.4 % and 39.6 %, respectively).ConclusionGiven the low resistance rates to levofloxacin and minocycline, these antibiotics may be considered as potentially effective options for treating S. maltophilia infections in Iran. Trimethoprim-sulfamethoxazole showed comparatively higher resistance rates, suggesting that its clinical efficacy may be declining. The rising isolation of S. maltophilia from clinical specimens in recent years, compared to the previous decade, is of both epidemiological and clinical concern, highlighting the need for ongoing surveillance and prudent antibiotic use.
Abstract licence: CC BY-NC-ND
Laurence Philippon, Thierry Naas, Anne-Typhaine Bouthors, et al.
Antimicrobial Agents and Chemotherapy, 1997
- Amino Acid Sequence
- Base Sequence
- beta-Lactamases
Dominique Larrey, Thierry Vial, Alain Micaleff, et al.
Gut, 1992
- Age Factors
- Amoxicillin
- Clavulanic Acids
Blair Je, McLeod Rs, Z. Cohen, et al.
PubMed, 1987
- Premedication
- Clavulanic Acids
- Clinical Trials as Topic
Paul G. Higgins, Hilmar Wisplinghoff, Danuta Stefanik, et al.
Antimicrobial Agents and Chemotherapy, 2004
- beta-Lactamase Inhibitors
- Tazobactam
- Acinetobacter Infections
Rosa Fanci, C. Paci, Fabiana Leoni, et al.
Journal of Chemotherapy, 2003
- Amikacin
- Ceftazidime
- Clavulanic Acids
Fajian Hou, Li J, Lizhen Gao, et al.
PubMed, 1998
- Tazobactam
- Anti-Bacterial Agents
- Enzyme Inhibitors
Pamela Hunter, K. Coleman, Jackie Fisher, et al.
Journal of Antimicrobial Chemotherapy, 1980
- Amoxicillin
- Ampicillin
- Bacteria
Licea-Herrera JI, Guerrero A, Mireles-Martínez M, et al.
2024
Pseudomonas aeruginosa is an opportunistic pathogen with a high capacity to adapt to different factors. The aim of this study is to analyze the pathogenicity in P. aeruginosa strains and their resistance to heavy metals and antibiotics, in agricultural soil of the state of Tamaulipas, Mexico. Susceptibility to 16 antibiotics was tested using the Kirby-Bauer method (CLSI). Eight virulence factors (FV) and six genes associated with heavy metal resistance were detected by PCR. As a result, P. aeruginosa was detected in 55% of the samples. The eight virulence factors were identified in ≥80% of the strains. The strains showed some level of resistance to only three antibiotics: 32.8% to ticarcillin, 40.8% to ticarcillin/clavulanic acid and 2.4% to aztreonam. The most frequent heavy metal resistance genes were arsC (92.8%) and copA (90.4%). However, copB and arsB genes were also identified in a percentage greater than 80%, and the least frequent genes were merA in 14.4% and czcA in 7.2%. Although P. aeruginosa strains showed a high percentage of factor virulence (potential ability to cause infections), their high levels of susceptibility to antibiotics lead to the assumption that infections are easily curable.
Abstract licence: CC BY
Robert J. Fass, Richard B. Prior
Antimicrobial Agents and Chemotherapy, 1989
- beta-Lactamase Inhibitors
- Tazobactam
- Anti-Bacterial Agents
Sources: aggregated from Europe PMC (EMBL-EBI), OpenAlex, Crossref, PubMed and other open scholarly databases. Retracted articles are excluded. Study information is provided for research purposes and does not constitute medical advice.
Scientific data (pharmacology, interactions, ADME) is not yet available for this medicine. Clinical sections are sourced from the NHS dm+d database.